Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Enterprise Value of -$277.0 million for Q1 2026, up 13.48% sequentially from -$320.2 million in Q4 2025, and down 136.71% YoY from $754.7 million in Q1 2025.
Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Enterprise Value for 7 years, with the latest figure at -$277.0 million in Q1 2026.
- Quarterly Enterprise Value fell 136.71% year-over-year to -$277.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$277.0 million (down 136.71% YoY) and the FY2025 annual result came in at -$320.2 million, down 129.57% from the prior year.
- Enterprise Value advanced to -$277.0 million in Q1 2026 per TSHA's latest filing, from -$320.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$36.9 million in Q3 2022 and troughed at -$320.2 million in Q4 2025.
- A 5-year average of -$158.8 million and a median of -$141.9 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 80.7% in 2022, then sank 344.68% in 2023.
- Over 5 years, Enterprise Value stood at -$36.9 million in 2022, then tumbled by 290.84% to -$144.4 million in 2023, then grew by 3.4% to -$139.5 million in 2024, then tumbled by 129.57% to -$320.2 million in 2025, then climbed by 13.48% to -$277.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$277.0 million, -$320.2 million, and -$297.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | -455.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -455.41 Mn |
| Mar 31, 2026 | -277.05 Mn |
| Dec 31, 2025 | -320.22 Mn |
| Sep 30, 2025 | -297.79 Mn |
| Jun 30, 2025 | -313.21 Mn |
| Mar 31, 2025 | -117.04 Mn |
| Dec 31, 2024 | -139.49 Mn |
| Sep 30, 2024 | -158.14 Mn |
| Jun 30, 2024 | -173.19 Mn |
| Mar 31, 2024 | -124.43 Mn |
| Dec 31, 2023 | -144.39 Mn |
| Sep 30, 2023 | -164.28 Mn |
| Jun 30, 2023 | -45.08 Mn |
| Mar 31, 2023 | -63.43 Mn |
| Sep 30, 2022 | -36.94 Mn |
| Jun 30, 2022 | -66.24 Mn |
| Mar 31, 2022 | -99.27 Mn |
| Dec 31, 2021 | -151.74 Mn |
| Sep 30, 2021 | -191.41 Mn |
| Jun 30, 2021 | -197.37 Mn |